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Abstract:
Background: Acinetobacter baumannii (AB) is increasingly becoming a clinically relevant organism due to the rising number of  
associated nosocomial infections. The therapeutic options are extremely minimal because of  its ability to develop resistance to 
all available antimicrobials, including colistin (CST). Data on the clinical and microbiological characteristics of  colistin-resistant 
A. baumannii infections remain scarce to date.
Methods: In this prospective study, clinical isolates of  colistin resistance among Acinetobacter strain was evaluated from the da-
tabase of  Microbiology Laboratory of  King Khalid University Hospital, Saudi Arabia.
Results: In a total of  142 patients with 136 Acinetobacter isolates, Acintobacter baumannii was the predominant serotype 73% of  
the isolates and Acinetobacter lwoffii constituted 27% of  the isolate .There was 8.5% colistin resistant isolates with colistin E-test 
MIC >4. The clinical characteristics were determined for colistin resistant Acinetobacter baumannii. All patients were critically ill 
and 64% of  them were hositalized in the Intensive Care Unit (ICU). All patients have been previously given antibiotics. Other 
associated clinical characteristics included; morbid obesity and sleeve gastrectomy (21 %), mechanical ventilation and central 
venous catheter (50%). High mortality rate was found(28%).
Conclusion: There is an increase of  colistin resistance among clinical isolates of  Acinetobacter baumannii causing serious infec-
tions especially in critically ill patients.
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Introduction
Acinetobacter baumannii (AB) is one of  the important multi-
drug resistant Gram-Negative nosocomial pathogens. It is 
responsible for many serious infections such as pneumo-
nia, sepsis, urinary tract and wound infections.1 Multiple 
factors lead to colonization with Acinetobacter baumannii, 
such as prolonged hospital stay, post- surgical procedures, 
ICUadmission and prior treatment with broad spectrum 
antibiotics.2,3 Recently, Acinetobacter strains exhibited ele-
vated rates of  carbapenem resistance (as high as 58%).4 
Colistin, a natural substance produced by Bacillus polymyxa 
and a cationic lipopeptide (cyclic decapeptide) was dis-
covered in 1949. Colistin was considered as  one  of   the 
last therapeutic options for treatment of  the multiresis-
tant Acinetobacter baumannii infection.5 It has been recom-
mended for the treatment of  ventilator associated pneu-
monia  caused by drug resistant  gram negative organism.6 
Recently colistin has been used as  rescue  therapy  for 
severe infection.7  However, resistance to colistin has re-
cently been described worldwide.8-12 Few data on Acineto-
bacter spp. infection and colistin resistance in Saudi Arabia 
is currently found in the literature.13,14 The objectives of  
the present study were to evaluate the clinical characteris-
tics, antimicrobial susceptibility testing and outcomes of  




This study was a prospective review conducted in a teach-
ing hospital located in Riyadh, Saudi Arabia using the Mi-
crobiology Laboratory database and the daily patients’ 
records from February 2015 through April 2016.
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Bacterial isolates
A total of  136 non-duplicate clinical isolates of  Acineto-
bacter isolates obtained from 142 patients, of  which 14 pa-
tients had multiple infections with different Acinetobacter 
species. Various specimens were collected from different 
sites including blood, genitourinary tract, respiratory tract 
and  wounds  specimens. Multidrug resistant bacteria are 
described as being resistant to at least one agent in three 
or more antibiotic categories.
Antimicrobial susceptibility testing
The identification of  the isolates and colistin susceptibility 
testing were  performed  by Vitek 2 (bioMérieux, France), 
and the colistin-resistant MICs were  confirmed by  E 
test methods, according to CLSI recommendations.15 The 
E  test  method  was  previously validated on the micro-
biology laboratory using broth microdilution (Trek Diag-
nostics Systems), according to CLSI recommendations.15 
The susceptibility categories were interpreted according 
to break-points of  CLSI guidelines.16 for non-fermenta-
tive isolates and EUCAST.17 for Enterobacteriaceae mem-
bers. Colistin minimum inhibitory concentrations (MICs) 
>2 µg/mL were considered resistant.18
Patient’s clinical data
The clinical characteristics associated with acquiring mul-
tiresistant Acinetobacter baumannii were determined by re-
viewing the clinical data recorded in the patient’s medical 
chart.
Results
Characteristics of  isolates
Of  the 227 Acinetobacter isolates obtained from (142) pa-
tient, 64 duplicate isolates  were excluded. Total of  163 
Acinetobacter isolates were  included and 10% (14/142) had 
more than one site of  infection. Almost 41.8% (68/163) 
of  the Acinetobacter isolates were multidrug resistant. Over 
the study period, the prevalence of  monthly reported 
Acinetobacter spp. was recorded in the data base of  the 
Microbiology laboratory  and it was steadily increasing 
reaching the highest prevalence (30%) of  the total  136 
Acinetobacter  isolates which was observed in March (2016) 
[Figure 1].
 
                                                                Figure 1: Prevalence of 136  Acinetobacter  species isolates over the study period 
Acinetobacter baumannii isolates 119 (73%) were the most 
common identified isolates of  all Acinetobacter species. 
Fourteen Acinetobacter baumannii isolates (14/163, (8.6%) 
were colistin resistant, (MIC: ≥ 4 mg/ml).
Site of  infection
The most common sites of  specimens included respira-
tory tract (6/14; 42%), urine (2/14; 14%), wound (1/14; 
7%), blood (4/14; 28%), and tissue (1/14; 7%).
Clinical and demographics of  patients
Demographic data and associated clinical characteristics 
and comorbid diseases that were more prevalent in the 14 
patients infected with colistin resistant Acinetobacter bau-
mannii are illustrated in [Table 1]. 
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Of  the 14 patients between the age of  (12-91), there were 
9 male (64%) and 5 females (35%) and one pediatric pa-
tient (7%) who had lymphoma. Nine patients were admit-
ted in the intensive care unit (64%). Four (28%) patients 
had diabetes mellitus and hypertension. chronic renal fail-
ure, morbid obesity, and sleeve gastrectomy were identi-
fied in 3 patients (21%) respectively. Sleeve gastrectomy 
was done one year, seven months and three months prior 
to the study in three patients.  Seven (50%) patients were 
mechanically ventilated. Central line and urinary catheter 
were used in (50%,43%) respectively. Prior hospitaliza-
tion was documented in all A. baumannii colistin resistant 
infected patients(100%). All patients received antibiotics 
before the diagnosis of  AB infection including carbap-
enem (78.5%) colistin (28%), vancomycin (64%), tazo-
cin (50%), linezolid (14%), aminoglycoside (14%) and 
antifungal agents (43%). High mortality rate (28%) was 
found among patients with AB colistin resistant infection 
in spite of  intensive treatment. Treatment of  patients in-
cluded colistin in combination with aminoglycosides or 
carbapenem. Data obtained after analyzing resistance to 
AB strains isolated showed that this bacteria’s antibiotic 
resistance was high. The Minimum Inhibitory Concen-
tration (MIC) of  colistin against the various Acinetobacter 
baumannii for which the MIC E-test was performed is pre-
sented in [Table 2].
Table 1. Clinical characteristics of patients infected with colistin  
resistant Acinetobacter baumannii 
  
Clinical characteristics n=14 % 
Age (mean) 12yr-91yr.   
Gender     
- Male 9 63 
- Female 5 41 
Admission     
- ICU 9 64 
- Medical 6 43 
- Surgical 3 21 
Medical/Surgical Comorbidity:     
- Diabetes mellitus 4 28 
- Hypertension 4 28 
- Morbid Obesity 3 21 
- Chronic renal failure 3 21 
- Heart disease 4 28 
- Malignancy 2 14 
- Immunosuppression 1 7 
- Septic shock 2 14 
- Surgery 5 35 
- Sleeve Gastrectomy 3 21 
Hospitalization (last 3 months) 7 50 
Invasive devices     
- Mechanical ventilation 7 50 
- Central venous catheter 7 50 
- Urinary catheter 5 35 
Death 4 28 
                                                           ICU; Intensive Care Unit 
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Table 2. Previous antibiotics used for the last 3 months in 
patients with Acinetobacter baumannii infection 
  
Antibiotic N % 
- Total 14 100 
- Colistin 5 35 
- Carbapenem 10 71 
- Glycopeptide (vancomycin) 9 64 
- Cephalosporin 3 21 
- Aminoglycoside 2 14 
- Quinolone 0 0 
- Piperacillin-tazobactam 7 50 
- Linezolide/daptomycine 2 14 
- Tigecycline 1 7 
- Metronidazole 2 16 
- Antifungal 6 43 
  
Discussion
In this study the prevalence of  Acinetobacter isolates was 
found to be steadily increasing. This finding was report-
ed by other studies; a study from Iran showed that, the 
prevalence of  drug resistance among the clinical samples 
of  A.baumannii isolated against most of  the antibiotics is 
very high.19 Another study from Romania has shown that 
a large number of  A. baumannii strains were resistant to 
the tested antibiotics. The lowest resistance was recorded 
for ampicillin and sulbactam and the highest resistance 
rate was recorded for ceftazidime and imipenem.20-24
Acinetobacter baumannii isolates were the most common 
identified isolates of  all Acinetobacter species, (73%) this 
finding was similar to other studies.25,26
In this study a large number of  colistin-resistant/carbap-
enem-resistant A.  baumannii was observed. Similar to our 
finding, the emergence of  colistin resistant  A.  baumannii 
has been observed in several countries.27-30
A study from Central Greece showed a significant in-
crease of  colistin-resistant/carbapenem-resistant A. bau-
manniias a total of  86 colistin-resistant/carbapenem-re-
sistant out of  1228 A. baumannii were collected between 
2012 and 2014.31
The age of  the patients was variable between 4-90 years; 
all of  them were critically ill and had chronic disease such 
as hypertension, chronic renal failue, morbid obesity and 
malignancy. All of  them had prior hospital admission and 
were treated with different antibiotics including carbap-
enem, aminoglycoside and vancomycin. More than 50% 
of  the patients required central line and urinary catheters.
Knowledge of  these possible risk factors for Colistin-re-
sistant A. baumannii is a challenge for antibiotic treatment 
and infection control policies. We found that the majority 
of  the patients were admitted in the intensive care unit 
(64%). Mechanical ventilation in (50%), Prior hospital 
admission and antibiotic use were documented in all pa-
tients (100%).  Similar findings were reported by Qureshi 
et al; in his study all patients but one were in the ICU at 
the time of  isolation of  colistin- resistant A. baumannii 
and (65%) of  the patient used ventilator.32
In this study, among the antibiotics that had been used 
previously carbapenem was used in (78.5%) of  the pa-
tients, while colistin was used in (28%). In Qureshi et al 
study,95% of  the patients had received intravenous and/
or inhaled colistin for the treatment of  carbapenem-re-
sistant, colistin-susceptible A. baumannii infection prior to 
identification of  colistin-resistant isolates.32
Another study from Turkey reported that previous 
quinolone use in the last three months (P=.003; RR:3.2; 
95% CI:1.5-6,7) and previous colistin use in the last three 
months (P=.001; RR: 3.6; 95% CI: 1.63-7.99) were sig-
nificant risk factors in the multivariate analysis associated 
with infection by colistin-resistant microorganisms.33
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In spite of  intensive treatment, 28% of  our patients died 
by 30  days.  A study  from  USA reported high mortality 
rates among almost all  patients with colistin resistance 
AB and suffering from ventilator-associated pneumoni-
ae.32 Another  study  from  Brazil reported 7 out of  20 
isolates were colistin resistant and 8 patients died during 
therapy.34
                     
A retrospective cohort study was conducted in the med-
ical/surgical ICU at Zhongshan Hospital in Shanghai, 
China. Adult patients meeting the criteria of  A.baumannii 
VAP from January 2012 to October 2015 were enrolled.
Seventy-eight patients were included in this study. The 
30-day mortality rate in ICU for the patients was 37.2%.35 
We believe that this is a high mortality rate in comprasion 
to our study where the mortality rate was (28%).
To our knowledge, our study involved 14 unique patients 
with infection due  to colistin-resistant AB.
The most important limitation of  this study was that it 
was of  a small number of  samples, probably because it 
was a prospective study that was carried out in relatively 
short time. Despite all limitations, this study represents 
the largest series describing clinical characteristics of  
colistin-resistant AB. Our data highlights an emerging 
clinical problem. Hence, early detection and optimization 
of  infection control practices are required.
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